Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-06-02 18:08:16 ET · period of report 2026-06-01 · accession 0001894425-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-02 18:08 | 2026-06-01 | NBIX | Onyia Jude | CSO | M - OptEx | $84.74 | +11.0K | 36.8K | +43% | +$932.1K |
| DT | 2026-06-02 18:08 | 2026-06-01 | NBIX | Onyia Jude | CSO | S - Sale+OE | $160.25 | -11.0K | 25.8K | -30% | -$1.76M |
| DT | 2026-06-02 18:08 | 2026-06-01 | NBIX | Onyia Jude | CSO | M - OptEx | $0.00 | -11.0K | 13.3K | -45% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | M | A | 11,000 | $84.74 | 36,846 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-01 | S | D | 11,000 | $160.25 | 25,846 | D | — | — | (F1) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Derivative | Non-Qualified Stock Option | 2026-06-01 | M | D | 11,000 | $0.00 | 13,268 | D | $84.74 · — to 2031-11-29 | 11,000 Common Stock | (F3) Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. |